Sarah Romero
Nurse Practitioner · Morgan City, LANPI 1265821326
Payments from drug & device makers
Across 148 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$404
- Amgen$306
- AstraZeneca$262
- Novartis$207
- Takeda Pharmaceuticals U.S.A., Inc.$173
- Johnson & Johnson$153
- plus $943 from 19 others
What the payments were for
- Food & beverage$2,449100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 21 | $404 |
| Amgen | 21 | $306 |
| AstraZeneca | 17 | $262 |
| Novartis | 15 | $207 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $173 |
| Johnson & Johnson | 10 | $153 |
| Amarin Pharma, Inc. | 5 | $102 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $102 |
| AbbVie | 6 | $100 |
| Merck | 6 | $95 |
| Boehringer Ingelheim | 5 | $93 |
| Novo Nordisk | 6 | $91 |
| Lilly USA, LLC | 3 | $61 |
| Esperion Therapeutics, Inc. | 3 | $52 |
| Exact Sciences | 2 | $33 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Itamar Medical Inc | 1 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Bayer | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| GSK | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Corium, LLC | 2 | $18 |
| Tactile Systems Technology Inc | 1 | $16 |
How this compares
$2,449 in reported general payments places this provider in the 80th percentile of 969 nurse practitioner providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 42 | $46,467 |
| XareltoRivaroxaban | 55 | $31,920 |
| LinzessLinaclotide | 52 | $29,670 |
| EliquisApixaban | 43 | $28,286 |
| EntrestoSacubitril/Valsartan | 38 | $20,788 |
| OzempicSemaglutide | 20 | $20,231 |
| MounjaroTirzepatide | 18 | $19,853 |
| GemtesaVibegron | 61 | $14,881 |
| JardianceEmpagliflozin | 33 | $13,509 |
| JanuviaSitagliptin Phosphate | 43 | $12,198 |
| VascepaIcosapent Ethyl | 18 | $7,551 |
| JanumetSitagliptin Phos/Metformin Hcl | 26 | $7,424 |
| TrintellixVortioxetine Hydrobromide | 13 | $4,278 |
| Potassium Chloride | 163 | $3,202 |
| Colchicine | 27 | $3,049 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $153 | $31,92055 claims |
| AbbVieLinzess | $100 | $29,67052 claims |
| PfizerEliquis | $404 | $28,28643 claims |
| NovartisEntresto | $207 | $20,78838 claims |
| Novo NordiskOzempic | $91 | $20,23120 claims |
| Lilly USA, LLCMounjaro | $61 | $19,85318 claims |
| MerckJanuvia, Janumet | $95 | $19,62269 claims |
| Boehringer IngelheimJardiance | $93 | $13,50933 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $173 | $4,27813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 969 nurse practitioner providers in Louisiana.
Other nurse practitioner in Morgan City
- Karen DeshotelLafayette$264K
- Christopher ManuelKaplan$145K
- Tammy BennettShreveport$99K
- Jessica BordelonHammond$78K
- Teri DugganBossier City$67K
- Matt LandryLafayette$50K
- Cynthia CobbLafayette$48K
- Ellen GentileWest Monroe$31K
- Reghan LittlepageAlexandria$24K
- April WoodrowOpelousas$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.